Irvine Scientific Introduces PRIME-XV T Cell Culture Medium for Immunotherapy Applications

Irvine Scientific has announced the introduction of PRIME-XV T Cell Expansion XSFM, a xeno-free and serum-free medium. PRIME-XV T Cell Expansion XSFM is a medium optimized for the expansion of human T cells that reliably maintains potency and is the newest medium in the PRIME-XV cell therapy product line that supports immunotherapy.

Immunotherapy has emerged as a viable approach for treating some forms of cancer. Using a process called adoptive cell transfer (ACT), T cells have been engineered to produce chimeric antigen receptors (CARs), a surface receptor that allows T cells to recognize tumour-specific proteins and subsequently kill the targeted tumour cells. This method has generated positive results in small clinical trials, indicating its potential as a treatment. To further support the research and development into ACT, efficient expansion of desired T cell subsets with proper potency is critical to ensure an adequate population of T cells with targeted specificity.

“Immunotherapy offers significant hope, particularly in the area of novel cancer treatment options,” said Dr Jessie H.-T. Ni, Chief Scientific Officer at Irvine Scientific. “We have developed this new medium using the most up-to-date knowledge of T cell biology to deliver improved performance over serum-containing and other existing commercial xeno-free, serum-free media in supporting ex vivo quality expansion of various human T cell subsets.”

Irvine Scientific supports immunotherapy with products and services for cancer stem/initiating cell expansion and tumorsphere formation, mesenchymal stem/stromal cell expansion, and a full suite of recombinant human growth factors to supplement any variety of applications. To facilitate clinical applications and scale-up, PRIME-XV T Cell Expansion XSFM is available for custom formulation and packaging.